NCT06497452 A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
| NCT ID | NCT06497452 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Soochow University |
| Condition | B-cell Non-Hodgkin Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2024-06-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess the efficacy and safety in the real-world settings of glofitamab in combination with salvage therapy among Chinese adult patients with relapsed or refractory B-cell non-hodgkin lymphoma.
Eligibility Criteria
Inclusion Criteria: * Be diagnosed as B-NHL * Relapse or refractory to previous treatment * Participants who will be treated with glofitamab Exclusion Criteria: * Participant who currently participates in or with plan to participate in any interventional clinical trial * Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06497452 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying B-cell Non-Hodgkin Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06497452 currently recruiting?
Yes, NCT06497452 is actively recruiting participants. Contact the research team at huanghaiwen@suda.edu.cn for enrollment information.
Where is the NCT06497452 trial being conducted?
This trial is being conducted at Suzhou, China.
Who is sponsoring the NCT06497452 clinical trial?
NCT06497452 is sponsored by The First Affiliated Hospital of Soochow University. The trial plans to enroll 50 participants.